title: Bone metabolism in 2012: Novel osteoporosis targets.
abstract: Researchers are trying to develop more efficient and safer antifracture treatments. Besides the ongoing promising clinical trials involving antibodies to the Wnt antagonist sclerostin or inhibition of the osteoclast enzyme cathepsin K, the year 2012 has seen several novel osteoporosis targets identified by using different methodological approaches.
authors.affiliation: Centre for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Sweden. claes.ohlsson@medic.gu.se
authors.forename: Claes
authors.initials: C
authors.lastname: Ohlsson
mesh_terms: D000818:Animals; D015519:Bone Density; D004064:Digestive System / Q000378:metabolism / Q000382:microbiology; D055106:Genome-Wide Association Study; D006801:Humans; D015201:Meta-Analysis as Topic; D010024:Osteoporosis / Q000188:drug therapy* / Q000235:genetics* / Q000382:microbiology; D040121:Semaphorin-3A / Q000378:metabolism
chemical_list: D040121:Semaphorin-3A